je.st
news
GenVec Inc (GNVC) Rating Increased to Buy at Zacks Investment Research
2016-02-06 19:17:43| Biotech - Topix.net
The firm currently has a $0.50 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's price target indicates a potential upside of 2.02% from the company's previous close.
Tags: buy
research
rating
increased
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||